Nonalcoholic fatty liver disease: an update.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
28
4
2023
pubmed:
1
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
We discuss two recent controversial issues in the research field of fatty liver: the proposal to replace nonalcoholic fatty liver disease (NAFLD) with metabolically associated fatty liver disease (MAFLD) and the suggestion to extend to primary care the noninvasive testing for liver fibrosis that was developed for secondary care. There is preliminary evidence that MAFLD-only patients are at greater risk of fibrosis than NAFLD-only patients. There are a large number of false positives associated with the downshift of noninvasive testing for liver fibrosis from secondary to primary care. More studies are needed to compare the MAFLD and NAFLD operational definitions. Noninvasive testing of liver fibrosis also needs further evaluation before it can be used in primary care or in the general population.
Identifiants
pubmed: 36853834
doi: 10.1097/MOL.0000000000000874
pii: 00041433-202306000-00005
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114-118Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158:1999.e1–2014.e1.
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73:202–209.
Singh SP, Anirvan P, Reddy KR, et al. Nonalcoholic fatty liver disease: not time for an obituary just yet. J Hepatol 2021; 74:972–974.
Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021; 73:1194–1198.
Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic fatty liver disease (NAFLD) name change: Requiem or Reveille. J Clin Translat Hepatol 2021; 9:931–938.
Bedogni G, Gastaldelli A, Foschi FG. Fatty liver, cardiometabolic disease and mortality. Curr Opin Lipidol 2020; 31:27–31.
Mayo DG. Statistical Inference as severe testing. Cambridge: Cambridge University Press; 2018.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2016; 64:1388–1402.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640–1645.
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - what is it and how should it be managed. Eur J Prev Cardiol 2019; 26:33–46.
van Kleef LA, Ayada I, Alferink LJM, et al. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology 2022; 75:419–429.
Harrell F. Regression modeling strategies. Switzerland: Springer: Cham; 2016.
Riley RD, Van der Windt D, Croft P, Moons KGM. Prognosis research in healthcare. Oxford: Oxford University Press; 2019.
Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the nonoverlap groups. Liver Int 2022; 42:277–287.
van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach. Hepatology 2022; 76:1243–1245.
Greenland S. Invited commentary: the need for cognitive science in methodology. Am J Epidemiol 2017; 186:639–645.
Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007; 92:396–398.
Allen AM, Therneau TM, Ahmed OT, et al. Clinical course of nonalcoholic fatty liver disease and the implications for clinical trial design. J Hepatol 2022; 77:1237–1245.
Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021; 70:1375–1382.
Jacobson IM, Wong VW, Castera L, et al. Expert panel consensus on clinical assertion statements describing noninvasive tools for diagnosing nonalcoholic steatohepatitis. J Clin Gastroenterol 2022; doi: 10.1097/MCG.0000000000001780. [Online ahead of print].
doi: 10.1097/MCG.0000000000001780.
Sajid IM, Frost K, Paul AK. ‘Diagnostic downshift’: clinical and system consequences of extrapolating secondary care testing tactics to primary care. BMJ Evid Based Med 2022; 27:141–148.
Foschi FG, Domenicali M, Giacomoni P, et al. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population. Ann Hepatol 2020; 19:380–387.
van Dijk AM, Vali Y, Mak AL, et al. Noninvasive tests for nonalcoholic fatty liver disease in a multiethnic population: the HELIUS study. Hepatol Commun 2022.
Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol 2022; 20:2567.e6–2576.e6.